Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

GlobeNewswire
2025.11.19 12:03
portai
I'm PortAI, I can summarize articles.

NEW YORK, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Cellectis ( the "Company" ) ( Euronext Growth: ALCLS - NASDAQ: CLLS ) , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes an article in Nature ...

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer